论文部分内容阅读
目的:研究脱甲氧基姜黄素磷脂复合物在大鼠体内的药代动力学特征。方法:分别给予SD大鼠脱甲氧基姜黄素磷脂复合物混悬液和游离药物脱甲氧基姜黄素后,不同时间点于大鼠眼底静脉丛取血。采用高效液相法测定血浆中脱甲氧基姜黄素的浓度。结果:脱甲氧基姜黄素磷脂复合物的药代动力学参数如下:AUC0-t为(693.306±128.55)μg/(L·h),是游离药物脱甲氧基姜黄素的1.96倍;AUC0-∞为(716.174±123.18)μg/(L·h),较脱甲氧基姜黄素提高了1.93倍;脱甲氧基姜黄素磷脂复合物的Cmax为(95.044±6.95)μg/L,Tmax为(0.17±0)h。结论:脱甲氧基姜黄素磷脂复合物相对于脱甲氧基姜黄素而言,其生物利用度具有明显的提高,且制剂脱甲氧基姜黄素磷脂复合物和游离药物脱甲氧基姜黄素生物等效性不合格。
Objective: To study the pharmacokinetics of demethoxy curcumin phospholipid complex in rats. Methods: SD rats demethoxy curcumin phospholipid complex suspension and free drug demethoxy curcumin, at different time points in the rat venous plexus blood. The concentration of demethoxycurcumin in plasma was determined by HPLC. Results: The pharmacokinetic parameters of the demethoxycurcumin phospholipid complex were as follows: AUC0-t was (693.306 ± 128.55) μg / (L · h), 1.96 times that of the free drug demethoxycurcumin; AUC0 -∞ was (716.174 ± 123.18) μg / (L · h), which was 1.93 times higher than that of demethoxy curcumin. The Cmax of demethoxycurcumin phospholipid complex was (95.044 ± 6.95) μg / L and Tmax (0.17 ± 0) h. CONCLUSION: The demethoxycurcumin phospholipid complex has a significant increase in bioavailability relative to demethoxycurcumin, and the preparation of the demethoxycurcumin phospholipid complex and the free drug demethoxy turmeric Prime bioequivalence failed.